• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS Live: STAAR Surgical looks toward the future of eye care

Video

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

Warren Foust, chief operating officer of STAAR Surgical, discussed the company and looked toward the future at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Warren Foust:

I'm Warren Foust. I'm the chief operating officer of STAAR Surgical. San Diego has been an amazing meeting. We're coming down to the end but we've had such a wonderful time here at STAAR Surgical.

The EVO ICL continues to gain in popularity—a wonderful showing at the Eyecelerator meeting, which we were grateful to be part of, and also [an] amazing time with so much traffic at our booth. I'm grateful to Ophthalmology Times for bringing us to this forum.

I just want to say how excited I am to be part of STAAR Surgical and also want to say how exciting of a time it is for refractive surgery. STAAR [Surgical] is the only company in the space that is truly investing in our customers' ability to grow the refractive practice. Patients around the world—2 million strong—have given us amazing reaction to the implantation of the EVO ICL, 99.4% would say they're satisfied. In a recent study of over 900 surgeons, we got similar levels of satisfaction. So really excited about that. What we've learned through that process is that a happy EVO ICL patient grows a refractive practice.

I wish each one of you good luck as you start to engage with us. Please look for us at the booth the rest of the time. Please spend time with our teams. We're happy to market with you. We're happy to be part of the refractive market with you. Thank you.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.